Streetbeat News

ECOR

electroCore, Inc.

https://www.electrocore.com

Industry

Medical - Devices

electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.

Open

13.48

Mkt cap

89M

Volume

64K

High

14.03

P/E Ratio

-7.82

52-wk high

15.25

Low

13.22

Div yield

N/A

52-wk low

5.21

electroCore, Inc. (NASDAQ:ECOR) has announced the commercial launch of TAC-STIM, a non-invasive vagus nerve stimulator designed in partnership with the US military to enhance human performance for active-duty military use.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 12:05 pm

electroCore (ECOR) will join the Russell Microcap Index effective after the close on June 28.

Portfolio Pulse from Benzinga Newsdesk

June 11, 2024 | 12:13 pm

electroCore has announced a $9.3 million registered direct offering of one share of common stock, sold together with one-half of one warrant at a combined effective offering price of $6.4925. Additionally, the company is conducting separate concurrent private placements priced at market under Nasdaq rules.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 12:52 pm

electroCore (NASDAQ:ECOR) reported Q1 2024 earnings with a GAAP EPS of $(0.53), surpassing the $(0.61) estimate, and sales of $5.443M, exceeding the $4.767M estimate. This represents a significant improvement over the previous year, with a 57.26% decrease in losses per share and a 95.79% increase in sales.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 8:58 pm

In Wednesday's after-market session, health care stocks saw significant movements with CytomX Therapeutics, ZimVie, and Aesthetic Medical Intl leading the gains, while Etao International, Enhabit, and Myomo were among the top losers. Most movements were influenced by the release of Q1 earnings.

Portfolio Pulse from Benzinga Insights

May 08, 2024 | 8:31 pm

electroCore, Inc. has announced the launch of Truvaga Plus, a new product aimed at enhancing general wellness. This development could potentially open new market segments for the company and drive revenue growth.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 12:44 pm

electroCore, Inc. (NASDAQ:ECOR), a bioelectronic medicine company, announced the receipt of two new patents from the USPTO, enhancing its intellectual property in non-invasive vagus nerve stimulation (nVNS) technology. The patents, issued on April 2, 2024, cover a system for nerve stimulation via a mobile device and methods for treating central nervous system disorders with electrical impulses.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 12:18 pm

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterated a Buy rating on electroCore (NASDAQ:ECOR) and maintained a $15 price target.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 10:52 am

electroCore (NASDAQ:ECOR) reported Q4 2023 GAAP EPS of $(0.61), meeting analyst consensus estimates, with sales of $5.191M surpassing the $4.967M estimate, marking a 102.77% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 8:07 pm

Numerous companies are scheduled to report their earnings on March 13, 2024, covering a wide range of industries from biotech to retail. Notable mentions include Dollar Tree with expected earnings of $2.65 per share on $8.67 billion revenue, and Lennar with an estimate of $2.20 per share on $7.39 billion revenue. Several companies are anticipated to report losses, such as ZIM Integrated Shipping with a projected loss of $1.29 per share.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 10:15 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.